Bright Minds Biosciences Inc.
NASDAQ:DRUGBiotechnology
+$0.62 today
- Market cap
- $204.78M
- Beta
- -0.11
- P/E (TTM)
- -29.8
- EPS (TTM)
- -$2.87
Volume 0.14M
Average 0.27M
DRUG Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Bright Minds Biosciences Inc.NASDAQ: DRUG
Net Income · Q2 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q2 FY2026 net income of CA$10.63M (cash outflow) rose 260.4% year over year, behind the +699.2% change in trailing-twelve-month net income. Sequentially, it rose 40.6% from the prior quarter. Over 3 fiscal years it compounded at -6.5% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate of -CA$44.87M (+266.9%) for the fiscal year ending Sep 2026, a slowdown from the +336.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -CA$10.63M+40.6% QoQ
- Last fiscal yearSep 2025
- -CA$12.23M+336.5% YoY
- LTMMar 2026
- -CA$27.53M+699.2% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
CAD · from the cash flow
- Latest · FY2025
- (12.23M) CAD
- Year-over-year change
- -336.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | (12.23M) | -336.5% |
| FY2024 | 2024-09-30 | (2.8M) | +62.0% |
| FY2023 | 2023-09-30 | (7.37M) | +50.7% |
| FY2022 | 2022-09-30 | (14.96M) | -73.0% |
| FY2021 | 2021-09-30 | (8.65M) | — |
Net Income vs competitors
How DRUG compares with its peers on the latest reported figures
No competitor Net Income figures are available to compare.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | (8.65M) | (14.96M) | (7.37M) | (2.8M) | (12.23M) |
| Depreciation & Amortization | 0 | 6.04K | 72.45K | 73.36K | 76.87K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 880.62K | 875.06K | 1.15M | 839.77K | 3.18M |
| Change in Working Capital | 306.08K | 724.13K | (941.72K) | 39.81K | 554.99K |
| Accounts Receivables | (110.15K) | (45.63K) | 118.8K | (13.24K) | (362.85K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 416.23K | 769.77K | (1.06M) | 53.06K | 917.84K |
| Other Non-Cash Items | 144.76K | (227.4K) | 65.1K | (1.18K) | (276.84K) |
| Operating Cash Flow | (7.32M) | (13.59M) | (7.02M) | (1.85M) | (8.69M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | (7.16K) | (86.11K) | (89.73K) | (100.15K) |
| Common Stock Issued | 27.74M | 4.03M | 1.22M | 900.3K | 86.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.69M) | 1.17M | 1.06M | 0 | (360.14K) |
| Financing Cash Flow | 26.06M | 5.2M | 2.19M | 810.57K | 85.57M |
| Effect of Forex Changes | 223.79K | 258.82K | (45.35K) | 11.72K | 312.63K |
| Net Change in Cash | 18.96M | (8.13M) | (4.88M) | (1.03M) | 77.19M |
| Free Cash Flow | (7.32M) | (13.59M) | (7.02M) | (1.85M) | (8.69M) |
Bright Minds Biosciences Inc.
NASDAQ:DRUG
Intrinsic Alpha fair value
Locked
Current Price
$20.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.